regorafenib

This page shows the latest regorafenib news and features for those working in and with pharma, biotech and healthcare.

FDA clears Blueprint’s $32k-per-month GI cancer drug

imatinib) and Pfizer’s Sutent (sunitinib), which are also available as generics, and Bayer’s Stivarga (regorafenib) which is still in patent.

Home-grown colorectal cancer drug approved in China

Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting.
Another IO knockback as Tecentriq combo fails phase III trial

cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population. ... The results from IMblaze370 were consistent with this prior monotherapy experience, showing that
NICE backs Pfizer’s Xeljanz for RA

Meanwhile, NICE has decided to remove Bayer’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the
Bayer's Nexavar backed by NICE for liver cancer

Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with
EMA clears Bayer's Stivarga for liver cancer

The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the

More from news
Approximately 7 fully matching, plus 30 partially matching documents found.

Pharma deals during August 2013

To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.